Abstract
BackgroundThe sphingosine 1-phosphate (S1P) receptor modulator FTY720P (Gilenya®) potently reduces relapse rate and lesion activity in the neuroinflammatory disorder multiple sclerosis. Although most of its efficacy has been shown to be related to immunosuppression through the induction of lymphopenia, it has been suggested that a number of its beneficial effects are related to altered endothelial and blood–brain barrier (BBB) functionality. However, to date it remains unknown whether brain endothelial S1P receptors are involved in the maintenance of the function of the BBB thereby mediating immune quiescence of the brain. Here we demonstrate that the brain endothelial receptor S1P5 largely contributes to the maintenance of brain endothelial barrier function.MethodsWe analyzed the expression of S1P5 in human post-mortem tissues using immunohistochemistry. The function of S1P5 at the BBB was assessed in cultured human brain endothelial cells (ECs) using agonists and lentivirus-mediated knockdown of S1P5. Subsequent analyses of different aspects of the brain EC barrier included the formation of a tight barrier, the expression of BBB proteins and markers of inflammation and monocyte transmigration.ResultsWe show that activation of S1P5 on cultured human brain ECs by a selective agonist elicits enhanced barrier integrity and reduced transendothelial migration of monocytes in vitro. These results were corroborated by genetically silencing S1P5 in brain ECs. Interestingly, functional studies with these cells revealed that S1P5 strongly contributes to brain EC barrier function and underlies the expression of specific BBB endothelial characteristics such as tight junctions and permeability. In addition, S1P5 maintains the immunoquiescent state of brain ECs with low expression levels of leukocyte adhesion molecules and inflammatory chemokines and cytokines through lowering the activation of the transcription factor NFκB.ConclusionOur findings demonstrate that S1P5 in brain ECs contributes to optimal barrier formation and maintenance of immune quiescence of the barrier endothelium.
Highlights
The sphingosine 1-phosphate (S1P) receptor modulator FTY720P (GilenyaW) potently reduces relapse rate and lesion activity in the neuroinflammatory disorder multiple sclerosis
FTY720P and a selective S1P5 agonist enhance transendothelial electrical resistance To investigate the role of S1P5 in brain Endothelial cell (EC) barrier function, we measured paracellular resistance formation by hCMEC/D3 cells while exposed to either FTY720P or the selective S1P5 agonist [31] by means of electrical cell-substrate impedance sensing (ECIS)
Our results show that S1P receptor activation by the nonselective S1P receptor agonist FTY720P significantly increases barrier formation in comparison with control cells (Figure 2a)
Summary
The sphingosine 1-phosphate (S1P) receptor modulator FTY720P (GilenyaW) potently reduces relapse rate and lesion activity in the neuroinflammatory disorder multiple sclerosis. Most of its efficacy has been shown to be related to immunosuppression through the induction of lymphopenia, it has been suggested that a number of its beneficial effects are related to altered endothelial and blood–brain barrier (BBB) functionality To date it remains unknown whether brain endothelial S1P receptors are involved in the maintenance of the function of the BBB thereby mediating immune quiescence of the brain. The vasculature of the brain is specialized to function as a barrier to protect the central nervous system (CNS) by restricting entry of unwanted molecules and immune cells into the brain This so-called blood–brain barrier (BBB) is composed of highly specialized brain endothelial cells (ECs) that line the capillary wall. The identification of targets to restore impaired barrier function may provide novel tools for treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.